Live news related to ABIVAX stock (FR0012333284): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on ABIVAX mainly cover share price moves, analyst notes et M&A activity. The stock trades at €93,05 on Euronext Paris, down 6,62% at the last update. This page lists the articles published on ABIVAX stock to track the share price, company announcements and any item likely to influence market perception.
The Paris-based biotech is losing ground this Tuesday in a declining market, while short seller positions on the stock have increased by one percentag…
The Parisian biotech company closes down this Monday, following the publication of its first-half 2026 results. The stock loses ground as the SBF 120 …
The Parisian biotech continues its downward summer trend, losing ground in a Paris market itself slightly in the red. The decline widens the gap from …
The Parisian biotech company is losing ground this Friday, in a context of a well-oriented market, with the CAC 40 up more than 1% during the session.…
The Paris-based biotech is posting a sharp decline on Monday in a nearly stable Paris market, bringing its monthly loss to over 13%. The stock, which …
Abivax announced positive feedback from the FDA following its pre-NDA discussions concerning obefazimod. This regulatory validation occurs before the …
After an extraordinary twelve-month stock market performance, the French biotech takes a new pause during the session. The stock is among the largest …
The French biotech takes a brief pause after an extraordinary twelve-month stock market journey. The stock dips in early afternoon in a balanced Paris…
The French biotech takes a new break during the session, in a Parisian market heavily affected by the resurgence of tensions in the Middle East. Howev…
The French biotech consolidates during the session, just days after securing its financing in the United States. The stock remains technically overhea…
